Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
<p>Abstract</p> <p>Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous dr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-07-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | http://www.ehoonline.org/content/1/1/17 |
| _version_ | 1818233714064228352 |
|---|---|
| author | Gadó Klára Matolcsy András Csomor Judit Kicsi Dóra Bödör Csaba Domján Gyula |
| author_facet | Gadó Klára Matolcsy András Csomor Judit Kicsi Dóra Bödör Csaba Domján Gyula |
| author_sort | Gadó Klára |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission. There is no available data concerning the optimal duration of dasatinib therapy. We report the case of an imatinib intolerant patient who succeeded a complete molecular remission with dasatinib. Dasatinib was stopped bacause of intolerance, but complete molecular remission was sustained for one year and minor molecular remission for 27 months after discontinuation of dasatinib.</p> |
| first_indexed | 2024-12-12T11:26:34Z |
| format | Article |
| id | doaj.art-6e683dd3ded245448f316853ca5bf160 |
| institution | Directory Open Access Journal |
| issn | 2162-3619 |
| language | English |
| last_indexed | 2024-12-12T11:26:34Z |
| publishDate | 2012-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj.art-6e683dd3ded245448f316853ca5bf1602022-12-22T00:25:54ZengBMCExperimental Hematology & Oncology2162-36192012-07-01111710.1186/2162-3619-1-17Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemiaGadó KláraMatolcsy AndrásCsomor JuditKicsi DóraBödör CsabaDomján Gyula<p>Abstract</p> <p>Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission. There is no available data concerning the optimal duration of dasatinib therapy. We report the case of an imatinib intolerant patient who succeeded a complete molecular remission with dasatinib. Dasatinib was stopped bacause of intolerance, but complete molecular remission was sustained for one year and minor molecular remission for 27 months after discontinuation of dasatinib.</p>http://www.ehoonline.org/content/1/1/17Chronic myeloid leukemiaDasatinibImatinibTyrosine kinase inhibitorDrug intolerance |
| spellingShingle | Gadó Klára Matolcsy András Csomor Judit Kicsi Dóra Bödör Csaba Domján Gyula Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia Experimental Hematology & Oncology Chronic myeloid leukemia Dasatinib Imatinib Tyrosine kinase inhibitor Drug intolerance |
| title | Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia |
| title_full | Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia |
| title_fullStr | Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia |
| title_full_unstemmed | Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia |
| title_short | Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia |
| title_sort | long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia |
| topic | Chronic myeloid leukemia Dasatinib Imatinib Tyrosine kinase inhibitor Drug intolerance |
| url | http://www.ehoonline.org/content/1/1/17 |
| work_keys_str_mv | AT gadoklara longlastingcompletemolecularremissionaftersuspendingdasatinibtreatmentinchronicmyeloidleukemia AT matolcsyandras longlastingcompletemolecularremissionaftersuspendingdasatinibtreatmentinchronicmyeloidleukemia AT csomorjudit longlastingcompletemolecularremissionaftersuspendingdasatinibtreatmentinchronicmyeloidleukemia AT kicsidora longlastingcompletemolecularremissionaftersuspendingdasatinibtreatmentinchronicmyeloidleukemia AT bodorcsaba longlastingcompletemolecularremissionaftersuspendingdasatinibtreatmentinchronicmyeloidleukemia AT domjangyula longlastingcompletemolecularremissionaftersuspendingdasatinibtreatmentinchronicmyeloidleukemia |